Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Deferred Revenue (2016 - 2020)

Amicus Therapeutics' Current Deferred Revenue history spans 8 years, with the latest figure at $1.2 million for Q1 2020.

  • For the quarter ending Q1 2020, Current Deferred Revenue fell 54.55% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Mar 2020, down 54.55%, and an annual FY2019 reading of $1.2 million, down 77.27% over the prior year.
  • Current Deferred Revenue for Q1 2020 was $1.2 million at Amicus Therapeutics, roughly flat from $1.2 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $18.8 million in Q2 2017, with the low at $1.2 million in Q4 2019.
  • Average Current Deferred Revenue over 5 years is $6.6 million, with a median of $5.4 million recorded in 2018.
  • Year-over-year, Current Deferred Revenue crashed 85.41% in 2018 and then skyrocketed 90.91% in 2019.
  • Tracing FOLD's Current Deferred Revenue over 5 years: stood at $13.8 million in 2016, then tumbled by 44.04% to $7.8 million in 2017, then dropped by 29.03% to $5.5 million in 2018, then plummeted by 77.27% to $1.2 million in 2019, then changed by 0.0% to $1.2 million in 2020.
  • Per Business Quant, the three most recent readings for FOLD's Current Deferred Revenue are $1.2 million (Q1 2020), $1.2 million (Q4 2019), and $5.2 million (Q3 2019).